Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Precision Biosciences (DTIL) Non-Current Deffered Revenue (2018 - 2025)

Precision Biosciences (DTIL) has disclosed Non-Current Deffered Revenue for 8 consecutive years, with $20.0 million as the latest value for Q3 2025.

  • On a quarterly basis, Non-Current Deffered Revenue fell 24.92% to $20.0 million in Q3 2025 year-over-year; TTM through Sep 2025 was $20.0 million, a 24.92% decrease, with the full-year FY2024 number at $23.3 million, down 68.12% from a year prior.
  • Non-Current Deffered Revenue was $20.0 million for Q3 2025 at Precision Biosciences, down from $20.2 million in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $131.2 million in Q1 2021 to a low of $20.0 million in Q3 2025.
  • A 5-year average of $63.6 million and a median of $73.1 million in 2023 define the central range for Non-Current Deffered Revenue.
  • Peak YoY movement for Non-Current Deffered Revenue: skyrocketed 99.05% in 2021, then plummeted 72.58% in 2025.
  • Precision Biosciences' Non-Current Deffered Revenue stood at $67.0 million in 2021, then rose by 23.66% to $82.9 million in 2022, then decreased by 11.81% to $73.1 million in 2023, then crashed by 68.12% to $23.3 million in 2024, then decreased by 14.35% to $20.0 million in 2025.
  • Per Business Quant, the three most recent readings for DTIL's Non-Current Deffered Revenue are $20.0 million (Q3 2025), $20.2 million (Q2 2025), and $20.5 million (Q1 2025).